TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have a history of seasonal allergic rhinitis~* Have a positive (as defined in the protocol) skin prick or RAST test within 12 months prior to the screening visit~Exclusion Criteria:~* Have a clinically significant illness or disease~* Have unstable asthma~* Has participated in a clinical trial 30 days prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bilastine 20 mg
- 2 (Type: ACTIVE_COMPARATOR): Fexofenadine 120 mg
- 3 (Type: ACTIVE_COMPARATOR): Cetirizine 10 mg
- 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotic Treatment Alone for Acute Simple Appendicitis in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 7-17 years~2. Radiologically confirmed simple appendicitis, defined as:~   a. Clinical findings: i. Unwell, but not generally ill ii. Localized tenderness in the right iliac fossa region iii. Normal/hyperactive bowel sounds iv. No guarding v. No mass palpable b. Ultrasonography: i. Incompressible appendix with an outer diameter of ≥6 mm ii. Hyperaemia within the appendiceal wall iii. Without fecalith iv. Infiltration of surrounding fat v. No signs of perforation vi. No signs of intra abdominal abscess/phlegmon~Exclusion criteria:~1. Patients with severe general illness at time of presentation:~   1. Generalized peritonitis defined as:~      Diffuse inflammation of the peritoneum with clinical signs consisting of increasing abdominal pain, generalized tenderness, diffuse abdominal rigidity, sinus tachycardia, signs of paralytic ileus~  2. Severe sepsis or septic shock, as defined by the international paediatric sepsis consensus conference \[39\]. See attachment 1.~  3. Signs of complex appendicitis~2. Children with a fecalith on ultrasonography.~3. Patients with serious associated conditions or malformations such as:~   1. Congenital or acquired cardiac or pulmonary disease with significant hemodynamic consequences~  2. Immunodeficiency~  3. Malignancy~  4. Homozygous sickle cell disease~  5. Metabolic disorders~4. Patient with documented type 1 allergy to the antibiotics used

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Antibiotic treatment alone (Type: EXPERIMENTAL): Intravenous administration:~Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7mg/kg once daily~Oral administration of:~Amoxicillin/clavulanic acid 50/12.5 mg/kg/day (in three doses)
- Appendectomy (Type: ACTIVE_COMPARATOR): Routine appendectomy either laparoscopic or open depending on the surgeon's preference

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years;~* ECOG PS 0-2;~* Histologically or cytologically documented unresectable and/or metastatic HCC;~* Measurable disease by RECIST criteria;~* Previous local therapy completed \> 6 weeks;~* Any acute toxicity (CTC-AE) \< grade 1;~* Child-Pugh A;~* Liver transaminases ≤ 5 x ULN;~* Albumin ≥ 2.8 g/dl;~* Serum total bilirubin ≤ 3 mg/dl;~* INR ≤ 2.3 or PT ≤ 6 seconds above control;~* WBC ≥ 3,000/µl;~* ANC ≥ 1,500/µl;~* Platelets ≥ 100,000/µl;~* Hb ≥ 8.5 g/dl;~* Creatinine ≤ 1.5 x ULN; AND~* Amylase and lipase \< 1.5 x ULN~Exclusion Criteria:~* Metastatic brain/leptomeningeal tumors;~* Prior or concomitant systemic anti-cancer treatment for HCC, including:~  * Systemic chemotherapy (TACE is allowed)~ * Immunotherapy~ * Hormonal therapy (hormonal therapy used for supportive used is allowed)~ * Raf-kinase inhibitors~ * MEK inhibitors~ * Farnesyl transferase inhibitors~ * VEGF/VEGFR- inhibitors or other anti-angiogenesis agents~ * Investigational anti-cancer agents~* Severe and/or uncontrolled medical conditions:~  * Uncontrolled high blood pressure~ * History of poor compliance with anti-hypertensive agents~ * Active or uncontrolled infection~ * Unstable angina~ * CHF~ * MI or CVA \< 6 months~ * GI bleeding \< 30 days~ * Unable to take oral medications~* Severe renal impairment which requires dialysis; proteinuria \> grade 2;~* BMT or stem cell rescue \< 4 months; organ transplant;~* HIV infection;~* Major surgical procedure, open biopsy, or significant traumatic injury \< 4 weeks or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 2 weeks;~* Receive central venous line placement within 7 days;~* Patients who anticipate receiving major surgery during the course of the study;~* Use rifampin, St. John's Wort \[Hypericum perforatum\];~* Patients taking narrow therapeutic index medications will be monitored closely. These include warfarin, phenytoin, quinidine, carbamazepine, phenobarbital, cyclosporine, and digoxin; OR~* Patients for whom tegafur is contra-indicated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects. Female subjects must be non-pregnant and non-lactating.~* 18 to 64 years of age inclusive at Screening~* Current or recent history of intolerance to milk and other dairy products~* Acceptable Baseline Lactose Intolerance Symptom Scores~* Acceptable Result on Baseline Hydrogen Breath Test~* Subjects must agree to refrain from all other treatments and products used for lactose intolerance during the study~Exclusion Criteria:~* Disorders known to be associated with abnormal GI motility~* History of surgery that alters the normal function of the gastrointestinal tract~* Past or present; organ transplant, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, Celiac disease, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS)~* Active gastric or duodenal ulcers or history of severe ulcers~* Diabetes mellitus (type 1 or type 2)~* Congestive Heart Failure~* History of Human Immunodeficiency Virus (HIV), Hepatitis B or C~* Use of concurrent therapy(ies) for symptoms of lactose intolerance~* Uncontrolled BP defined as sitting systolic blood pressure (SBP) ≥160 mmHg or diastolic blood pressure (DBP) ≥95 mmHg at Visit 1~* History of ethanol abuse in the past 12 months~* History of drug abuse within 12 months~* History or presence of malignancy within the past 5 years (except basal cell or squamous cell carcinoma removed from a sun-exposed area)~* Use of any investigational drug or participation in any investigational study within 30 days prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- RP-G28 (Type: EXPERIMENTAL): Study Drug RP-G28
- Placebo (Type: PLACEBO_COMPARATOR): Study Drug Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~-Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.~Exclusion Criteria:~* Previous enrollment in another Allergan Bimatoprost SR Study.~* Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye~* Anticipated need for laser eye surgery in either eye within the first 52 weeks of the study duration~* History of glaucoma surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimatoprost SR 15 μg (Type: EXPERIMENTAL): Study Eye: bimatoprost sustained release (SR) 15 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
- Bimatoprost SR 10 μg (Type: EXPERIMENTAL): Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
- Timolol 0.5% (Type: ACTIVE_COMPARATOR): Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma (MM) per the International Myeloma Working Group (IMWG) criteria~* Eligible for autologous stem cell transplantation (ASCT) per institutional guidelines~* Within 1 year of start of therapy for multiple myeloma~* Cardiac and pulmonary status sufficient to undergo apheresis and transplantation per institutional transplant guidelines~* Calculated creatinine clearance \> 30 mL/min, according to the Modification of Diet in Renal Disease (MDRD) formula.~* Absolute neutrophil count (ANC) \> 1500 x 10e6/L~* Platelet count \> 100,000 x 10e6/L~* Ability to understand and the willingness to sign a written informed consent document.~* Agreement to use an approved form of contraception for male patients or female patients of childbearing potential.~Exclusion Criteria:~* History of prior stem cell transplant for multiple myeloma or other indications~* Planned tandem stem cell transplant~* Prior history of failure to collect HSCs.~* Total bilirubin \> 1.5x upper limit of normal (ULN) in the absence of a documented history of Gilbert's syndrome~* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 3x ULN~* Known allergy to MGTA-145 or plerixafor.~* Lifetime exposure to lenalidomide or another immunomodulatory drug greater than 6 cumulative months of treatment, ie, \> 6 cycles of 28 days or \> 8cycles of 21 days~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MGTA-145 and Plerixafor HSC Mobilization (Type: EXPERIMENTAL): Patients after screening will undergo baseline evaluation during the premobilization phase up to 30 days before mobilization. Patients will undergo sequential administration of plerixafor 0.24 mg/kg subcutaneously followed 2 hours later by MGTA-145 at 0.03 mg/kg intravenously (3 to10 minute infusion). This will be followed by apheresis. A second day of mobilization and apheresis will be pursued in patients who have not collected 6.0 x 106 CD34+ cells/kg in one session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of a deceased donor kidney transplant at least 3 months after transplantation~* Urinary protein to creatinine ratio (UPCR) \> 200 mg/g (20 mg/mmol) as determined by the the mean of three second morning void urine specimens~* Subject is on stable immunosuppression for at least 3 months~* Subject is on stable doses of antihypertensive medications for at least 3 months~* Subject is not expected to begin dialysis for at least 6 months~* Estimated glomerular filtration rate \> 15 ml/min/1.73 m2~* Corrected serum calcium level \< 2.6 mmol/l~* Intact parathormone value \> 30 pg/ml~Exclusion Criteria:~* Subjects on vitamin D receptor activation therapy within 3 months prior to the first study visit~* Acute kidney injury within 3 months of the first study visit~* Subjects with poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paricalcitol (Type: ACTIVE_COMPARATOR): None
- Matching placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinically proved superficial bladder cancer (Ta G1/G2 or T1G1/G2) 2 - 7 weeks before transurethral resection~* Written informed consent for study participation and for documentation of disease data including further distribution of these data~Exclusion Criteria:~* Muscle invasive bladder carcinoma and/or carcinoma in situ (CIS)~* Intravesical instillation therapy within 6 months prior to study enrolment~* Radiotherapy of the bladder prior to study enrolment~* Contracted bladder (capacity less than 100 ml)~* Non treated acute or chronic urinary tract infection~* Allergy against mistletoe extract preparations~* Subvesical obstructions (e. g. prostate hyperplasia, urethral stenosis, residual urine volume more than 80 ml)~* Severe illnesses and circumstances not permitting study participation (e. g. alcoholism or substance abuse)~* Pregnancy or lactation (pregnancy test if required) as well as women without sufficient contraception~* Participation in another clinical study within 30 days prior to this study~* Administration of immunotherapeutic and/or cytostatic drugs within 4 weeks prior to study enrolment~* Chronic progressive infections (e. g. tuberculosis)~* Pre-treatment with mistletoe extracts/mistletoe lectins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dose escalation (Type: EXPERIMENTAL): intravesical instillation of abnobaVISCUM Fraxini

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven prostatic adenocarcinoma of the following TNM stages and WHO grades: T1 or T2 and grade G3 T3 or T4 and any histologic grade No evidence of distant metastases No evidence of positive common iliac or para-aortic lymph nodes Confirmed by bone scan, chest x-ray, negative ultrasound or CT of the liver, and CT of the retroperitoneum and/or bipedal lymphangiography Extraperitoneal pelvic lymph node biopsy may be either positive or negative provided stage and grade criteria are met~PATIENT CHARACTERISTICS: Age: Under 80 Performance status: WHO 0-2 Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of second malignancy except basal cell skin carcinoma~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for prostate cancer Endocrine therapy: No prior hormonal therapy for prostate cancer Radiotherapy: No prior radiotherapy for prostate cancer Surgery: No prior radical prostatectomy No prior transperitoneal lymph node staging

- Gender: MALE
- Minimum Age: None
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. The subject/patient is able to read and understand the subject/patient information sheet.~2. Prior to any screening procedures, the subject/patient must have signed the informed consent form. No study-related procedures may be performed before the subject/patient has signed the form.~3. Age 25-70 years~4. Heavy alcohol consumption (males more than 5 doses/ day, female more than 4 doses/day) for at least 10 years~5. Alcohol dependence (DSM-IV) assessed by SCID-I interview.~6. Major depression (DSM-IV) assessed by SCID-I interview. At least 4 weeks past from the previous inpatient treatment for AWS (alcohol withdrawal syndrome).~Exclusion Criteria:~1. Other drug dependence (screened by urine test)~2. Other serious mental illness (DSM-IV)~3. Hazard of suicide~4. Pregnancy~5. Serious kidney, hart or thyroid problem~6. The subject/patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.~7. Liver cirrhosis or liver enzymes ASAT tai ALAT \>200.~8. The person that met the criteria stated in the Finnish Law on Clinical Studies, paragraph 7-10§ (children, pregnant, imamates or mentally handicapped).

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* clinically and histologically proven painful bullous/erosive or atrophic forms of OLP~Exclusion Criteria:~* lichenoid lesions smoking systemic conditions pregnancy or breast feeding known hypersnstivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- tacrolimus/corticosteroid (Type: EXPERIMENTAL): topical steroids ( triamcinolone acetonide 0.1 %), tacrolimus paste and tacrolimus patch
- corticosteroids (Type: ACTIVE_COMPARATOR): topical corticosteroid
- tacrolimus (Type: ACTIVE_COMPARATOR): topical tacrolimus patch and tacrolimus paste

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age Normal vision in both eyes (20/30 best corrected) Preference for patient with dry eye symptoms~Exclusion Criteria:~* No ocular disease other than dry eye Currently taking no ocular or systemic medications that might affect results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Isotonic hyaluronate artificial tear (Type: EXPERIMENTAL): At random, subjects will receive isotonic hyaluronate artificial tear or a control (normal saline).
- Normal saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete